Why Trump’s plan to fast-track psychedelic approval deserves caution

President Donald Trump’s executive order to fund research into psychedelic therapies and fast-track their review has been widely lauded, and for good reason. Drugs such as psilocybin and MDMA have demonstrated striking results in clinical trials to treat depression, post-traumatic stress disorder an...

Redirecting to full article...